Table 3.
Source | Brain region | Predictor |
MTUS1
|
C14orf79
|
||||
---|---|---|---|---|---|---|---|---|
β | SE | P | β | SE | P | |||
Eisai Bio Bank (RNA-Seq) | HIPP | AD Status | 0.38 | 0.16 | 0.02 | 0.04 | 0.14 | 0.76 |
HIPP | Braak Stages | 0.16 | 0.04 | 3.9×10−4 | −0.07 | 0.03 | 0.06 | |
| ||||||||
Mt. Sinai Hospital (Microarray) | CER | AD Status | 0.00 | 0.02 | 0.78 | −0.13 | 0.02 | 7.5×10−8 |
DLPFC | AD Status | 0.09 | 0.04 | 0.01 | −0.13 | 0.02 | 3.3×10−7 | |
VCX | AD Status | 0.09 | 0.03 | 0.01 | −0.15 | 0.03 | 2.1×10−8 |
Brain regions tested were hippocampus (HIPP), cerebellum (CER), dorsolateral prefontal cortex (DLPFC), visual cortex (VCX). Positive effect (β) for AD status means that a gene is up-regulated in AD cases vs. in controls. Positive effect for Braak stages means that the expression of a gene is positively correlated with the Braak stages.